Literature DB >> 25141194

Microbes and cancer geography: can we exploit recent lessons from the gut system to oral cancer context?

Gustavo P Garlet1, Carlos F Santos2.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 25141194      PMCID: PMC4126818          DOI: 10.1590/1678-77572014ed004

Source DB:  PubMed          Journal:  J Appl Oral Sci        ISSN: 1678-7757            Impact factor:   2.698


× No keyword cloud information.
Dear Readers, In recent JAOS editorials, oral cancer[4] and oral microbes[3] were independently in the spotlight, and in this issue, two interesting studies[9,10] bring these topics together and lead us to an interesting discussion. Before considering the articles published in this JAOS issue, we must consider the aspects raised by Bongers, et al.[2] (2014); Garlet and Santos[3] (2014). In summary, the authors elegantly describe the interplay of host microbiota, genetic factors and inflammation in the development of intestinal neoplasms in mice. Using interesting experimental tools such as transgenic mice, and simple but insightful strategies such as broad-spectrum antibiotics treatment, the authors demonstrate a clear relationship between bacteria and site-specific cancer development. Interestingly, the results from Lira's group provide experimental evidence clearly in line with 'old' suggestions that bacteria 'might produce carcinogens'[1]. Evidently the cancer etiology is really complex, and translation of authors' findings to human cancer reality requires further investigation[3]. Also, while some microbes have been implicated as potential carcinogenesis trigger, probiotics microorganisms have been demonstrated to regulate intestinal inflammation and pointed as possible protective factors against the cancer development[6,8]. Back to oral cavity, one may argue that Bongers, et al.[2] (2014) data may be limited to the gut system, and that is premature to translate such finding to human oral cancer reality. However, recently an interesting parallel between the gut and oral cavity was drawn, originally focused on the host-microbe homeostasis (or the lack of) and its role in the health/disease outcome[5]. Interestingly, the gut and the oral cavity comprise a mucosal firewall in close contact with a highly diverse and abundant microbial flora. In both environments the disruption of gut host-microbe homeostasis has been associated with severe inflammatory pathologies. Please not that Bongers, et al.[2] (2014) study also demonstrates the central involvement of inflammation in intestinal cancer development, in accordance with several previous evidences. Therefore, gut and the oral cavity share features such as the mucosal nature associated with a profuse microbial flora, and the relatively common susceptibility for microbial-driven chronic inflammation. As previously mentioned, it is obviously premature to make any strong statement regarding a possible role of oral bacteria in oral cancer only based on the gut-mouth parallel, but two studies published in this edition of the JAOS may lead us to interesting considerations. Pan, et al.[9] (2014) from Shanghai's Stomatological Disease Centre and Jiao Tong University, demonstrate a high prevalence of drug-resistant microbes (such as methicillin resistant S. aureus [MRSA]) in oral cancer patients. While such finding is properly discussed by the authors within the study limitation, and primarily interpreted as a potential side effect of the compromised immune system due cancer treatment, one may argue if such microbes really appeared after the treatment. Indeed, the cross-sectional nature of the study does not allow the determination of the time of such microbes emergence, based on the association of microbes with gut cancer it is possible to speculate that specific bacteria could be not a cause (a co-factor perhaps) and not a consequence of cancer (and its immunosuppressive treatment). On the other hand, Zhang, et al.[10] (2014) from Jiamusi University and Qiqihaer Medical University in China demonstrate that Lactobacillus sp. A-2 metabolites have a potential role in the inhibition of growth and induction of apoptosis of human tongue squamous cell carcinoma CAL-27 cells in vitro. As discussed by the authors, probiotics microorganisms metabolites may have anti-tumor functions acting directly on cancer cells, but also may exert antimicrobial activities, which in theory also could interfere in cancer development, at least in the scenario described by Bongers, et al.[2] (2014). Again, we reinforce that the translation of experimental data from the gut to oral cancer reality might be only speculative at this time. In a very astute comment focused on the bacteria-cancer link in the gut, Jobin[7] (2014) discusses the existence of layers of complexity by highlighting the interplay between host genetics, microbial location, and tumor geography. The microbial contribution to cancer development in both gut and oral cavity environments evidently requires further investigation, but the similarities between both niches may provide additional valuable clues to direct future investigations.
  10 in total

Review 1.  Protection from gastrointestinal diseases with the use of probiotics.

Authors:  P R Marteau; M de Vrese; C J Cellier; J Schrezenmeir
Journal:  Am J Clin Nutr       Date:  2001-02       Impact factor: 7.045

Review 2.  Restoring host-microbe homeostasis via selective chemoattraction of Tregs.

Authors:  G P Garlet; C S Sfeir; S R Little
Journal:  J Dent Res       Date:  2014-07-23       Impact factor: 6.116

3.  Bacteria and the aetiology of cancer of the large bowel.

Authors:  V Aries; J S Crowther; B S Drasar; M J Hill; R E Williams
Journal:  Gut       Date:  1969-05       Impact factor: 23.059

4.  From Amazon rain forest flora to the state-of-the-art technology devices, the incessant search for 'magic bullets' against Streptococcus mutans.

Authors:  Gustavo Pompermaier Garlet; Carlos Ferreira Santos
Journal:  J Appl Oral Sci       Date:  2014-04       Impact factor: 2.698

5.  Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation.

Authors:  Robert R Jenq; Carles Ubeda; Ying Taur; Clarissa C Menezes; Raya Khanin; Jarrod A Dudakov; Chen Liu; Mallory L West; Natalie V Singer; Michele J Equinda; Asia Gobourne; Lauren Lipuma; Lauren F Young; Odette M Smith; Arnab Ghosh; Alan M Hanash; Jenna D Goldberg; Kazutoshi Aoyama; Bruce R Blazar; Eric G Pamer; Marcel R M van den Brink
Journal:  J Exp Med       Date:  2012-04-30       Impact factor: 14.307

6.  Do bugs define cancer geography?

Authors:  Christian Jobin
Journal:  J Exp Med       Date:  2014-03-10       Impact factor: 14.307

7.  Oral cavity infection: an adverse effect after the treatment of oral cancer in aged individuals.

Authors:  Jie Pan; Jun Zhao; Ning Jiang
Journal:  J Appl Oral Sci       Date:  2014 Jul-Aug       Impact factor: 2.698

8.  Apoptosis of human tongue squamous cell carcinoma cell (CAL-27) induced by Lactobacillus sp. A-2 metabolites.

Authors:  Guoliang Zhang; Jie Zhang; Xinyu Wang; Wenqin Yang; Zhihui Sun; Chaurasia Nitesh Kumar; Hong Guan; Jian Guan
Journal:  J Appl Oral Sci       Date:  2014 Jul-Aug       Impact factor: 2.698

9.  Interplay of host microbiota, genetic perturbations, and inflammation promotes local development of intestinal neoplasms in mice.

Authors:  Gerold Bongers; Michelle E Pacer; Thais H Geraldino; Lili Chen; Zhengxiang He; Daigo Hashimoto; Glaucia C Furtado; Jordi Ochando; Kevin A Kelley; Jose C Clemente; Miriam Merad; Harm van Bakel; Sergio A Lira
Journal:  J Exp Med       Date:  2014-03-03       Impact factor: 14.307

10.  Oral cancer: from bench to bedside, the continuous effort towards better diagnostic, treatment and prognostic tools.

Authors:  Gustavo Pompermaier Garlet
Journal:  J Appl Oral Sci       Date:  2013 Sep-Oct       Impact factor: 2.698

  10 in total
  1 in total

1.  Epigenetic and inflammatory events in experimental periodontitis following systemic microbial challenge.

Authors:  Daniela B Palioto; Livia S Finoti; Denis F Kinane; Manjunatha Benakanakere
Journal:  J Clin Periodontol       Date:  2019-06-25       Impact factor: 8.728

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.